Use of abatacept in rheumatoid arthritis
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as ea...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2012-05-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/1481 |
| _version_ | 1811194154024173568 |
|---|---|
| author | Johannes von Kempis Jean Dudler Paul Hasler Diego Kyburz Alan Tyndall Pascal Zufferey Peter M. Villiger |
| author_facet | Johannes von Kempis Jean Dudler Paul Hasler Diego Kyburz Alan Tyndall Pascal Zufferey Peter M. Villiger |
| author_sort | Johannes von Kempis |
| collection | DOAJ |
| description |
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.
|
| first_indexed | 2024-04-12T00:21:09Z |
| format | Article |
| id | doaj.art-661303abc11c4657b8908a1a6443d88f |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-12T00:21:09Z |
| publishDate | 2012-05-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-661303abc11c4657b8908a1a6443d88f2022-12-22T03:55:43ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972012-05-01142192010.4414/smw.2012.13581Use of abatacept in rheumatoid arthritisJohannes von KempisJean DudlerPaul HaslerDiego KyburzAlan TyndallPascal ZuffereyPeter M. Villiger Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts. https://www.smw.ch/index.php/smw/article/view/1481abataceptrecommendationsrheumatoid arthritistherapyuse |
| spellingShingle | Johannes von Kempis Jean Dudler Paul Hasler Diego Kyburz Alan Tyndall Pascal Zufferey Peter M. Villiger Use of abatacept in rheumatoid arthritis Swiss Medical Weekly abatacept recommendations rheumatoid arthritis therapy use |
| title | Use of abatacept in rheumatoid arthritis |
| title_full | Use of abatacept in rheumatoid arthritis |
| title_fullStr | Use of abatacept in rheumatoid arthritis |
| title_full_unstemmed | Use of abatacept in rheumatoid arthritis |
| title_short | Use of abatacept in rheumatoid arthritis |
| title_sort | use of abatacept in rheumatoid arthritis |
| topic | abatacept recommendations rheumatoid arthritis therapy use |
| url | https://www.smw.ch/index.php/smw/article/view/1481 |
| work_keys_str_mv | AT johannesvonkempis useofabataceptinrheumatoidarthritis AT jeandudler useofabataceptinrheumatoidarthritis AT paulhasler useofabataceptinrheumatoidarthritis AT diegokyburz useofabataceptinrheumatoidarthritis AT alantyndall useofabataceptinrheumatoidarthritis AT pascalzufferey useofabataceptinrheumatoidarthritis AT petermvilliger useofabataceptinrheumatoidarthritis |